{"id":"NCT00275821","sponsor":"Novartis","briefTitle":"Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)","officialTitle":"A Randomized, Double-masked, Active-controlled, Multi-center Study Comparing the Efficacy and Safety of Ranibizumab Administered as Two Dosing Regimens in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2006-01-12","resultsPosted":"2011-03-16","lastUpdate":"2011-03-16"},"enrollment":353,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Age Related Macular Degeneration"],"interventions":[{"type":"DRUG","name":"Ranibizumab 0.3 mg - 3 times monthly, then quarterly","otherNames":[]},{"type":"DRUG","name":"Ranibizumab 0.5 mg - 3 times monthly, then quarterly","otherNames":[]},{"type":"DRUG","name":"Ranibizumab 0.3 mg monthly","otherNames":[]}],"arms":[{"label":"Ranibizumab 0.3 mg - 3 times monthly, then quarterly","type":"EXPERIMENTAL"},{"label":"Ranibizumab 0.5 mg - 3 times monthly, then quarterly","type":"EXPERIMENTAL"},{"label":"Ranibizumab 0.3 mg monthly","type":"ACTIVE_COMPARATOR"}],"summary":"The study will test if the efficacy and safety of an alternative dosing regimen is as effective as monthly injections.","primaryOutcome":{"measure":"Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12","timeFrame":"Baseline to Month 12","effectByArm":[{"arm":"Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly","deltaMin":4.9,"sd":13.13},{"arm":"Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly","deltaMin":3.8,"sd":13.33},{"arm":"Ranibizumab 0.3 mg Monthly","deltaMin":8.3,"sd":11.31}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Switzerland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":120},"commonTop":["Eye pain (Study eye)","Conjunctival haemorrhage (Study eye)","Visual acuity reduced (Study eye)","Intraocular pressure increased (Study eye)","Ocular hyperaemia (Study eye)"]}}